STXS
Stereotaxis Inc

2,035
Mkt Cap
$209.06M
Volume
142,105.00
52W High
$3.59
52W Low
$1.54
PE Ratio
-7.97
STXS Fundamentals
Price
$2.33
Prev Close
$2.24
Open
$2.32
50D MA
$2.89
Beta
1.02
Avg. Volume
527,691.39
EPS (Annual)
-$0.2976
P/B
32.56
Rev/Employee
$193,654.68
Loading...
Loading...
News
all
press releases
STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics
Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.
Zacks·7d ago
News Placeholder
More News
News Placeholder
Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +50.00% and -13.21%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Misses Revenue Estimates
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of 0.00% and -0.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
News Placeholder
Mettler-Toledo (MTD) Beats Q3 Earnings and Revenue Estimates
Mettler-Toledo (MTD) delivered earnings and revenue surprises of +4.99% and +3.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of +21.98% and +3.92%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Tactile Systems Technology (TCMD) Beats Q3 Earnings and Revenue Estimates
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of +125.00% and +8.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
ISRG Rides on da Vinci 5 Momentum: Can This Growth Sustain?
Intuitive Surgical's Q3 results impress, with da Vinci 5 adoption driving 23% revenue growth, though sustaining this rapid momentum may pose new challenges ahead.
Zacks·23d ago
News Placeholder
Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval
STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry.
Zacks·1mo ago
News Placeholder
STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation
Stereotaxis partners with CardioFocus to commercialize the first robotic Pulsed Field Ablation system, aiming to revolutionize cardiac arrhythmia treatment.
Zacks·1mo ago
News Placeholder
STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System
Stereotaxis stock gains as Erasmus Medical adopts Genesis robotic system, marking a milestone in cardiac arrhythmia care.
Zacks·2mo ago

Latest STXS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.